SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Brief summary (registry, in English)

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

What you commit to

• Study type: Observational
• Planned participants: 4975
• From 3 May 2017 to the primary completion date, 29 Aug 2022
• 136 sites in 20 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (136)

Sites in registry order. Pick your city on the disease page to sort them by distance.